BR112013032687A2 - dispositivo para o controle em circuito fechado de gases de processo em uma usina para produzir minérios de metal diretamente reduzidos - Google Patents

dispositivo para o controle em circuito fechado de gases de processo em uma usina para produzir minérios de metal diretamente reduzidos

Info

Publication number
BR112013032687A2
BR112013032687A2 BR112013032687A BR112013032687A BR112013032687A2 BR 112013032687 A2 BR112013032687 A2 BR 112013032687A2 BR 112013032687 A BR112013032687 A BR 112013032687A BR 112013032687 A BR112013032687 A BR 112013032687A BR 112013032687 A2 BR112013032687 A2 BR 112013032687A2
Authority
BR
Brazil
Prior art keywords
plant
closed
loop control
process gases
reduced metal
Prior art date
Application number
BR112013032687A
Other languages
English (en)
Portuguese (pt)
Inventor
Cornelius Gauer Gauer
Frank Stowasser
Isabelle Sylvie Gallou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013032687A2 publication Critical patent/BR112013032687A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112013032687A 2011-06-21 2012-06-19 dispositivo para o controle em circuito fechado de gases de processo em uma usina para produzir minérios de metal diretamente reduzidos BR112013032687A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161499222P 2011-06-21 2011-06-21
PCT/EP2012/061756 WO2012175522A1 (en) 2011-06-21 2012-06-19 Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide

Publications (1)

Publication Number Publication Date
BR112013032687A2 true BR112013032687A2 (pt) 2016-08-30

Family

ID=46319784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032687A BR112013032687A2 (pt) 2011-06-21 2012-06-19 dispositivo para o controle em circuito fechado de gases de processo em uma usina para produzir minérios de metal diretamente reduzidos

Country Status (11)

Country Link
US (1) US9006270B2 (enExample)
EP (1) EP2723733A1 (enExample)
JP (1) JP2014517049A (enExample)
KR (1) KR20140033432A (enExample)
CN (1) CN103619840B (enExample)
BR (1) BR112013032687A2 (enExample)
CA (1) CA2839621A1 (enExample)
IN (1) IN2014DN00145A (enExample)
MX (1) MX2013014887A (enExample)
RU (1) RU2014101626A (enExample)
WO (1) WO2012175522A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
CA2865993A1 (en) * 2012-03-30 2013-10-03 Novartis Ag Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma
MX378409B (es) * 2013-12-06 2025-03-10 Novartis Ag Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
CN107106497A (zh) * 2014-10-03 2017-08-29 诺华股份有限公司 含alpelisib的药物组合物
AU2020257301B2 (en) 2019-04-18 2025-10-23 The Johns Hopkins University Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof
CN112961090A (zh) * 2019-12-13 2021-06-15 武汉九州钰民医药科技有限公司 合成Alpelisib的关键中间体及其制备方法
CN110964005A (zh) * 2019-12-16 2020-04-07 武汉九州钰民医药科技有限公司 一种Alpelisib的制备工艺
CN111057051A (zh) * 2019-12-16 2020-04-24 武汉九州钰民医药科技有限公司 PI3K抑制剂Alpelisib的新合成方法
JP7649637B2 (ja) 2020-10-06 2025-03-21 エルジー ディスプレイ カンパニー リミテッド 伝送装置及び表示システム
CN117279627A (zh) * 2021-05-03 2023-12-22 诺华股份有限公司 阿培利司配制品
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
WO2007129044A1 (en) * 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
US20140171470A1 (en) 2014-06-19
CN103619840A (zh) 2014-03-05
IN2014DN00145A (enExample) 2015-05-22
MX2013014887A (es) 2014-02-17
KR20140033432A (ko) 2014-03-18
JP2014517049A (ja) 2014-07-17
RU2014101626A (ru) 2015-07-27
CA2839621A1 (en) 2012-12-27
US9006270B2 (en) 2015-04-14
AU2012274141B2 (en) 2015-12-24
CN103619840B (zh) 2016-01-20
AU2012274141A1 (en) 2013-12-12
EP2723733A1 (en) 2014-04-30
WO2012175522A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
BR112013032687A2 (pt) dispositivo para o controle em circuito fechado de gases de processo em uma usina para produzir minérios de metal diretamente reduzidos
BR112014009790A2 (pt) composto para modulação antisense da expressão de gccr, seu uso e composição
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
BR112013021236A8 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
CO6612271A2 (es) Anticuerpos anti-cd40
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
PE20091458A1 (es) Compuestos heterociclicos antiviricos
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
UA111199C2 (uk) Співкристали l-проліну і лимонної кислоти з (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфеніл)тіофен-2-іл)метил)-4-метилфеніл)-6-(гідроксиметил)тетрагідро-2h-піран-3,4,5-тріолом
BR112013017236A2 (pt) produto de dessulfurização resistente a aglomeração para remover contaminantes de um fluxo de fluido, método para produzir um produto de dessulfurização resistente à aglomeração para remover contaminantes de um fluxo de fluido, e método para remover contaminantes de um fluxo de fluido
BR112013029999A2 (pt) derivados de tiazol
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
PE20160609A1 (es) Piperidil-etil-pirimidina sustituido como inhibidor de grelina o-acil transferasa
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
BR112014003602A2 (pt) método para a produção de um sal de metionina
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
MX2018001204A (es) Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil- 1h-bencimidazol-5-il)propanoico sustituido.
EA201990529A1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
BR112013032456A2 (pt) anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer
NZ601508A (en) Substituted naphthalenyl-pyrimidine compounds and the use thereof in the treatment of cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]